Detrusor Overactivity
13
1
1
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
15.4%
2 terminated out of 13 trials
77.8%
-8.7% vs benchmark
31%
4 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
Developing a Simple Test to Diagnose Overactive Bladder
USI and/or DO in Women With Cystocele Before and After Cystocele Repair
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
Refractory Urge Incontinence and Botox Injections
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity
Botulinum A Toxin in Patients With Parkinson's Disease